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1 Abstract (200 word limit) 
2 
2 Aim: To investigate the role of epithelial sodium channels (ENaC) on lung fluid clearance in 
3 response to normobaric hypoxia, twenty healthy subjects were exposed to 15 hours of hypoxia 
4 (FiO2=12.5%) on two randomized occasions: 1) inhaled amiloride (A) (1.5mg/5ml saline); and 2) 
5 inhaled saline placebo (P). Changes in lung fluid were assessed via chest CT for lung tissue 
6 volume (TV), and the diffusion capacity of the lung for carbon monoxide (DLCO) and nitric 
7 oxide (DLNO) for pulmonary-capillary blood volume (VC). Extravascular lung water (EVLW) 
8 was derived as TV-VC and changes in the CT attenuation distribution histograms were reviewed. 
10 
11 Results: Normobaric hypoxia caused 1) a reduction in EVLW (change from baseline for A vs. P, 
12 -8.5±3.8 vs. -7.9±5.2%,p<0.05), 2) an increase in VC (53.6±28.9 vs. 53.9±52.3%,p<0.05) 3) a 
13 small increase in DLCO (9.6±29.3 vs. 9.9±23.9%,p>0.05), and 4) CT attenuation distribution 
14 became more negative, leftward skewed, and kurtotic (p<0.05). 
15 
15 Conclusion: Acute normobaric hypoxia caused a reduction in lung fluid that was unaffected by 
16 ENaC inhibition via inhaled amiloride. Although possible amiloride-sensitive ENaC may not be 
17 necessary to maintain lung fluid balance in response to hypoxia, and it is more probable that 
18 normobaric hypoxia promotes lung fluid clearance rather than accumulation for the majority of 
19 healthy individuals. The observed reduction in interstitial lung fluid means alveolar fluid 
20 clearance may not have been challenged. 
22 
23 
21 Keywords: chest computed tomography (CT), diffusion capacity of the lungs for carbon 
22 monoxide and nitric oxide (DLCO/DLNO), epithelial sodium channels (ENaC)
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Acronym List: 
ASL: Airway surface liquid BSA: body surface area BMI: 
body mass index BP: blood pressure Cl- : chloride 
CRU: clinical research unit CT: computed tomography 
DLCO: Diffusion capacity of the lungs for carbon monoxide 
DLNO: Diffusion capacity of the lung for nitric oxide DM: 
alveolar-capillary membrane conductance EBC: exhaled 
breath condensate 
EBCNa: exhaled breath condensate sodium concentration 
EVLW: extravascular lung water 
ENaC: epithelial sodium channels 
EPI: epinephrine 
FVC: forced vital capacity 
FEV1: forced expiratory volume in one second of the FVC 
FEF25-75: forced expiratory flow at 25-75% of the FVC 
FiO2: fraction of inspired oxygen 
HAPE: high-altitude pulmonary edema 
HR: heart rate 
LLS: Lake Louise Score 
Hb: Hemoglobin 
Hct: hematocrit 
MEFV: maximal expiratory flow volume 
Na+: sodium 
NE: norepinephrine 
PAP: Pulmonary arterial pressure 
PV: plasma volume 
Q: cardiac output 
TR: tricuspid regurgitation 
TV: tissue volume 
VA: Alveolar volume 
VC: Pulmonary-capillary blood volume 
VO2MAX : maximal exercise capacity  
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23 Introduction 
24 Pulmonary edema results from an imbalance between forces driving fluid into the alveoli, 
25 QDPHO\6WDULQJ¶V/DZRIIOXLGILOWUDWLRQDQGWKHLQWHJULW\RIWKHDOYHRODU-capillary barrier and the 
26 biological mechanisms for its removal, primarily active sodium (Na+) transport, which 
27 osmotically drives water reabsorption from the alveolar space, and lymphatic drainage. Hypoxic 
28 pulmonary vasoconstriction plays a role in the development of high-altitude pulmonary edema 
29 (HAPE) (Motley and others 1947; Sartori and others 2004; Swenson 2013). The increase in 
30 capillary hydrostatic pressure results in an increase in net filtration of fluid from the capillary to 
31 the interstitial space. Fluid that has been filtered, but not reabsorbed from the interstitial space, is 
32 then removed by the pulmonary lymphatics. Stimulation of increased lung lymph flow can occur 
33 in response to beta-2 adrenergic receptor stimulation mediated by increases in catecholamines, 
34 and increases in ventilation. These events will deform the tissue lympathic vessels attach to, and 
35 thereby facilitate pumping and production of lymph (Ikomi and others 1991; Mahe and others 
36 1991; Pearse and others 2005; Zawieja 2009). Previous work by our group demonstrated that 
37 exposure to normobaric hypoxia increases ventilation and catecholamines and reduces lung fluid 
38 (Snyder and others 2006; Snyder and others 2008). The close proximity of the capillaries to the 
39 alveoli allows for optimal gas exchange, but this closeness also subjects the alveoli to potential 
40 fluid infiltration in conditions such as higher pulmonary artery pressure and increased pulmonary 
41 vascular resistance which can result in fluid accumulation in the interstitial space and if not 
42 cleared cause fluid to build up in the alveoli. Because of the inverse and exponential relationship 
43 between rate of diffusion and membrane thickness, increases in airway surface liquid (ASL) that 
44 are not quickly reabsorbed will increase the distance across the alveolar-capillary membrane and 
45 greatly impact rate of diffusion and alveolar-capillary membrane conductance (DM). Lungs must 
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46 be kept moist, but not wet for effective and efficient gas diffusion. The principal determinant of 
47 ASL depth is the mass of salt on the airway surface (Boucher 1999). 
48 Active transport of Na+ from the airspace through epithelial sodium channels (ENaC) and 
49 then across the basolateral membrane by Na+/K+ ATPase is believed to be the primary 
50 determinant of alveolar fluid clearance by creating an osmotic gradient, with ENaC-mediated 
51 Na+ absorption being the rate limiting step (Matthay and others 2002; Matthay and others 1996). 
52 The importance of ENaC in keeping the lungs moist, but not wet is supported by evidence which 
53 suggests: 1) mice with a non-functional ENaC will demonstrate a failure to thrive in neonates 
54 due to an inability to clear amniotic fluid from their lungs following birth (Hummler and others 
55 1996); 2) individuals with pseudohypoaldosteronism, characterized by a loss of ENaC function, 
56 have been shown to have excess ASL (Kerem and others 1999); and 3) the pathologically dry 
57 lungs of patients with cystic fibrosis is partially due to hyperaborption of Na+ by ENaC (Mall 
58 and others 2004). 
59 (YLGHQFHIRU(1D&¶VUROHLQDOYHRODUIOXLGFOHDUDQFHLVDEXQGDQWEXWOHVVFOHDULVWKH 
60 evidence that it is necessary for maintaining lung fluid balance, and if impairment of channel 
61 function is sufficient to cause pulmonary edema. Further, there is evidence for impairment in 
62 Na+ transport in individuals susceptible to HAPE. For example, Sartori et al. demonstrated that 
63 baseline nasal potential difference was lower and the amiloride-sensitive Na+ transport reduced 
64 in mountaineers susceptible to this condition (Sartori and others 2004). Sodium transport was 
65 shown to be further reduced with altitude exposure in HAPE susceptible individuals, although 
66 this reduction with altitude was not in amiloride-sensitive Na+ flux. In contrast, amiloride 
67 administration in rats caused a decrease in Na+ transport with no additional decrease with 
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68 exposure to hypoxia. These data suggest that the reductions in ENaC activity were responsible  
69 for the reduction in Na+ transport with hypoxia (Tomlinson and others 1999a) and this hypoxia 
70 induced reduction in Na+ transport has been suggested to be mediated by downstream reduction 
71 in ENaC channel expression (Gille and others 2014). Additionally, prophylactically taken beta 2-
75 DJRQLVW¶VFDQSUHYHQW+$3(LQWKHVXVFHSWLEOHVXEMHFWVGXULQJDOWLWXGHH[SRVXUH6DUWRULDQG 
76 others 2002) and stimulate amiloride-dependent lung fluid clearance in hypoxia exposed rats 
77 (Vivona and others 2001) by reversing the hypoxia-mediated reduction in Na+ transport. 
78 Therefore, the purpose of this study was to determine if ENaC is necessary for lung fluid 
79 clearance in response to normobaric hypoxia in healthy humans. We hypothesized that ENaC 
80 inhibition by amiloride would result in greater lung fluid accumulation evidenced by 1) an 
81 increase in lung tissue density (measured via computed tomography (CT)) and estimated 
82 extravascular lung water (EVLW), 2) an elevation in exhaled breath condensate Na+, where an 
83 increase in Na+ would suggest an increase in ASL depth as water as water follows salt, and 3) a 
84 reduction in diffusion capacity of the lungs due to alveolar fluid accumulation increasing the 
85 diffusion distance across the alveolar-capillary membrane.
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86 Materials and Methods 
87 
87 Subjects 
88 ^Twenty-three healthy non-smoking adults of average fitness (V02PEAK 106% predicted) 
89 agreed to participate in this study. The protocol was reviewed and approved by the Mayo Clinic 
90 Institutional Review Board, all participants provided written informed consent prior to study and 
91 all aspects of the study were performed according to the declaration of Helsinki. Exclusion 
92 criteria included 1) cardiovascular or pulmonary abnormalities; 2) history of renal disease; 3) 
93 obese (BMI >30); 4) pregnancy; 5) hospital contact restrictions or an inability to exercise. Two 
94 SDUWLFLSDQWVZHUHµVFUHHQIDLOXUHV¶RQH due to illness and the other due to hospital contact 
95 restrictions. In addition, one subject was removed from the hypoxic tent after four hours due to 
96 nausea and general malaise. As such, the data reported reflects the results of the twenty subjects 
97 who completed the study. 
99 
98 Protocol 
99 At an initial screening visit, 1) height and weight were measured, 2) a blood draw was 
100 taken to rule out anemia and 3) a pregnancy test was completed in female subjects. Next, 
101 baseline pulmonary function was measured before each subject performed a maximal exercise 
102 capacity test on a cycle ergometer. Those without any of the exclusion criteria were then exposed 
103 to ~15hours of normobaric hypoxia in a double-blind, crossover, and randomized fashion of two 
104 experimental conditions: 1) nebulized amiloride (A) (1.5mg in 5ml normal saline), and 2) saline 
105 placebo (P). The experimental conditions were performed on different occasions separated by > 
106 3 days. Changes in lung fluid from before to after hypoxic exposure were assessed via chest CT 
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107 for lung tissue volume (TV), exhaled breath condensate sodium concentration (EBCNa) for ASL 
108 sodium flux, and the diffusion capacity of the lungs for carbon monoxide (DLCO) and nitric 
109 oxide (DLNO) for the determination of pulmonary-capillary blood volume (VC). Extravascular 
110 lung water (EVLW) and changes in the CT attenuation distribution histograms were reviewed. 
111 A summary of the hypoxic exposure visit is provided in Figure 1. 
114 
112 Normobaric Hypoxia Exposure 
113 For both treatment visits, subjects arrived at the Mayo Clinic Clinical Research Unit 
114 (CRU) at 13:00 and a venous catheter was placed in a brachial or antecubital vein. Following 30 
115 minutes of quiet rest, a baseline blood draw was taken for measurement of complete blood count, 
116 serum catecholamines and plasma sodium and chloride. Baseline measurement of lung fluid and 
117 pulmonary arterial pressure were taken. Subjects were then transferred to the hypoxic tent (FiO2 
118 12.5%, PAO2 91.5mmHg) (Colorado Altitude Training, Boulder, CO) at approximately 16:00. 
119 Vital signs, including heart rate (HR), blood pressure (BP), respiratory rate, respiratory sounds, 
120 acute mountain sickness symptoms (modified Lake Louise Score (Savourey and others 1995); 
121 see supplemental material), as well as tent temperature, barometric pressure and CO2 level were 
122 assessed and recorded every two hours by a CRU nurse assigned to the patient. Although we did 
123 not measure urine output as part of the initial protocol, we observed and received feedback from 
124 the first six subjects that within a few hours of the initial nebulization the participants seemed to 
125 urinating more frequently on one visit compared to the other visit. Due to the known diuretic 
126 effects of oral amiloride in the kidney, and the known short surface half-life and subsequent 
127 absorption of nebulized amiloride across the lung epithelium (Knowles and others 1990b; Mentz 
128 and others 1986; Noone and others 1997), we thought this may have been a sign that the local 
nebulization amiloride was having quite rapid systemic effects. As such, we modified the 132 
protocol to record fluid input and output in all remaining subjects, so net fluid output could be 133 
quantified. Subjects wore a wrist pulse oximeter (Nonin WristOx 3100, Nonin Medical, Inc., 134 
Plymouth, MN) to allow for continuous HR and peripheral oxygen saturation (SpO2) monitoring 135 
during their time in the tent. The subjects remained in the tent overnight for a total of 15.3 ± 0.9 136 
hours. If subjects needed to use the rest room, they were fitted with a portable mask connected to 137 
a gas reservoir attached to a cylinder of the hypoxic gas (12.5% O2) until returning to the 138 
hypoxic tent. At around 6:00 the following morning (14.6 ± 0.9 hours post entry to the tent), the 139 
blood draw was repeated and followed by EBC collection inside the tent. A mask and gas 140 
reservoir were used to keep the subjects hypoxic during the CT and DLCO and DLNO 141 
measurements. Hemoglobin (Hb) and hematocrit (Hct) measured from the complete blood count 142 
completed by the Mayo Clinic Clinical Core Laboratory (Sysmex XE5000) were used to 143 
estimate the change in plasma volume (PV) using the following equation (Dill and Costill 1974): 144 
∆%	 = 		
	
 		
100 −		100 −		 − 1 	100 
Epinephrine (EPI) and norepinephrine (NE) were measured by the Mayo Clinic Clinical 145 
Research Unit immunochemical core laboratory using High Performance Liquid 146 
Chromatography.   147 
 148 
Drug Administration 149 
The randomization and preparation for the administration of nebulized amiloride (1.5mg 150 
in 5mL saline) and nebulized saline placebo (5mL saline) was performed by the Mayo Clinic 151 
CRU pharmacy ensuring that the study investigators, technicians, nursing staff and subjects were 152 
blinded. Amiloride and saline were nebulized using standard apparatus (ReliaMed) connected to 153 
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150 a room air supply flowing at 8L/min. Each treatment was administered at three time points 
151 during exposure to hypoxia: 1) upon entering the tent at 16:00; 2) 21:00; and 3) 4:00 the 
152 following morning. The investigators were unblinded after all subjects had completed the study. 
157 
153 Chest CT Assessment of Lung Fluid 
154 Chest CT measurements were performed before and 15.5 ± 0.9 hours following hypoxic 
155 exposure for both treatment visits. The CT protocol followed what has been previously used in 
156 our laboratory (Johnson and others 2012; Snyder and others 2006). Briefly, the same scanner 
157 (GE LiteSpeed spiral CT scanner, GE Healthcare) was used for all CT scans. A scout scan was 
158 performed on the baseline visit of each overnight stay to determine the location and size of the 
159 lungs. The non-contrast chest CT scan was obtained with 2.5 mm thick slices with a 1.2mm 
160 overlap initially and then reconstructed to 1.25mm with a 0.6mm overlap. Before the subject was 
161 UHPRYHGIURPWKHVFDQQHUDPDUNZDVSODFHGRQWKHVXEMHFW¶VVNLQWRGHVLJQDWHWKHDQDWRPLFDO 
162 location of the start of the scan and the table height and number of slices were recorded. The 
163 baseline scout scan was repeated for each hypoxic exposure visit (placebo and amiloride), but the 
164 table height and number of slices was kept consistent with what was done the first hypoxic 
165 exposure visit. A member of the study team was with the subject in the scanning room, and 
166 instructed the subject to take a maximal inhalation and hold their breath at the total lung 
167 capacity. At this time the study team signaled the radiology technician to complete the scan, and 
168 once through the scanner the subject was told they could relax and return to normal breathing. 
169 Although a gated spirometer was not used to control lung volumes, the difference between 
170 baseline and post exposure to hypoxia CT derived air volumes was on average less than 5%. 
171 The CT images were then analyzed using custom image analysis software (Apollo, VIDA 
172 Diagnostics). The analyses were completed by a lab member blinded to the condition of the 
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197 
198 
199 
200 
VXEMHFW¶V &7 VFDQ 7KH VRIWZDUH VHJPHQWV WKH LPDJH WR VHSDUDWH OXQJ WLVVue from surrounding 
structures. In each picture element, the lung density was assumed to be a linear combination of air 
which has a Hounsfield units = -1000, and lung tissue which has the density of water, HU= 0. As 
such, an element at -600 HU represents 40% tissue, and -300 HU would represent 70% tissue. A 
histogram analysis of the picture elements within the lung tissue area was performed to obtain a 
mean lung density in HU and a tissue volume by summation of all the elements in the lung fields. 
The density and tissue volumes (TV) can also be determined for individual lobes of the lung. 
Two different methods were used to assess lung water from the CT. First, an estimation of 
extravascular lung water (EVLW). Since the tissue volume measured from the CT scan consists 
of lung tissue, blood and water, we subtracted the pulmonary capillary blood volume obtained 
from the DLCO and DLNO measures to remove the blood component (EVLW = TV - VC). If we 
then assume tissue volume remains relatively constant between the pre and post scans, any 
change in the EVLW describes changes in lung fluid. Second, differences in EVLW between 
study conditions were estimated using a histogram analysis approach. Lung interstitial tissue was 
segmented from surrounding tissue, large airways, and blood vessels using segmentation 
algorithms built in MATLAB (Mathworks, Inc., Natick, MA). CT attenuation distributions were 
generated from the segmented images. Mean, skew, kurtosis, and full-width half-max (FWHM) 
were calculated from these distributions (Chase and others 2016). When the attenuation becomes 
less attenuated or more negative, more skewed to the left and/or more kurtotic this collectively 
suggest less fluid as the attenuation distribution is becoming less dense, and shifting away from 
ZDWHU¶V DWWHQXDWLRQ RI  +8 3UHYLRXV ZRUN KDV GHPRQVWUDWHG D VWURQJ SRVLWLYH FRUUHODWLRQ
between attenuation and extravascular lung water (Scillia and others 1999; Shaker and others 
2004).
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202 Measurement of Diffusion Capacity of the Lungs for Carbon Monoxide, Nitric Oxide and 
203 Assessment of Cardiac Output 
204 ^Before and 16.0+0.9 hours following hypoxic exposure for both treatment visits, DLCO 
205 and DLNO and cardiac output (Q) were measured simultaneously with the subjects in an upright 
206 seated position using the rebreathing technique with a 5-liter anesthesia bag containing 0.7% 
207 acetylene, 9% helium, 0.3% carbon monoxide (C18O), 40 PPM NO (diluted immediately before 
208 the test in the bag from an 800 PPM gas mixture) and 35% O2, at a respiratory rate of 32 
209 breaths/minute as described previously (Hsia and others 1995; Snyder and others 2006; Snyder 
210 and others 2005; Wheatley and others 2015; Wheatley and others 2011a; Wheatley and others 
211 2011b; Wheatley and others 2013). The volume of gas placed in the bag was a standardized 
212 volume of 1575mL for all resting measures to ensure the bag did not collapse during inhalation, 
213 but also did not cause an unnecessary excess of gas in the bag during the maneuver. Bag volume 
214 was reduce to 1050mL in one subject. At the end of a normal expiration (functional residual 
215 capacity), the subjects were switched into the rebreathe bag and instructed to nearly empty the 
216 bag with each breath for 8-10 consecutive breaths. The maneuver was performed in triplicate 
217 before and after hypoxic exposure (performed immediately following completion of the CT 
218 scan). 
219 The rate of disappearance of acetylene from the exhaled gas mixture during rebreathing is 
220 used to assess pulmonary blood flow. Since acetylene does not bind to hemoglobin, the rate of 
221 disappearance of acetylene is limited primarily by the rate at which a new volume of blood is 
222 transported through the lungs. Because all the blood in the pulmonary circulation per minute is 
223 equal to the volume of blood in the systemic circulation per minute, the measure of the 
disappearance of acetylene provides a reliable measure of cardiac output and has previously been 224 
validated in our laboratory using direct Fick during exercise (Johnson and others 2000; Liu and 225 
others 1997).   226 
The diffusing capacity of the lungs for carbon monoxide is based on the contribution of 227 
both the membrane conductance and the hemoglobin binding and described by the equation 228 
developed by Roughton & Forester (Tamhane and others 2001).  229 
1
DLCO = 
1
DMCO
+ 
1
θCOVC
	
The rate of disappearance of the gases with each breath is calculated from the slope of the 230 
exponential disappearance for each gas with respect to helium using custom software(Snyder and 231 
others 2005).  Unlike DLCO, DLNO is theoretically based solely on membrane conductance as 232 
nitric oxide is scavenged 8000 times faster by hemoglobin than O2 so its uptake into the blood is 233 
nearly instantaneous. Although currently being debated, DLNO has been considered a relatively 234 
direct measure of membrane conductance (DMNO) as the diffusion resistance of the blood is 235 
trivial (Hsia 2002; Hsia and Raskin 2005; Roughton and Forster 1957b; Tamhane and others 236 
2001), but not infinite, and for our purposes of comparing change in response to a stimulus gives 237 
reliable results (Coffman and others 2016).  Using this assumption, the DMNO value is used to 238 
calculate the DM for carbon monoxide (DMCO) by adjusting for differences in diffusion constants 239 
based on molecular weight and solubility between the two gases as described previously using an 240 
alpha ratio of 2.2 (Tamhane and others 2001; Wheatley and others 2010b). Pulmonary-capillary 241 
blood volume (VC) is then calculated from the DLCO measured by subtracting the resistance to 242 
diffusion associated with alveolar-capillary barrier (DMCO) and correcting for differences in the 243 
rate of uptake and binding to hemoglobin (1/θ) due to differences in Hb concentrations and the 244 
alveolar pressure of oxygen as described previously using the Roughton and Forester 2.5 ӨCO 245 
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246 equation (Roughton and Forster 1957a; Tamhane and others 2001; Wheatley and others 2010b). 
247 This technique has been validated in our laboratory and used extensively for studies in other 
248 clinical populations (Olson and others 2006; Snyder and others 2006; Snyder and others 2008; 
249 Wheatley and others 2011a; Wheatley and others 2011b). 
250 
250 Pulmonary Function Testing 
251 Baseline spirometry was assessed on the screening visit according to American Thoracic 
252 Society guidelines (Medical Graphics CPXD, Minneapolis, MN) to determine forced vital 
253 capacity (FVC), forced expiratory volume in one second of the FVC (FEV1) and forced 
254 expiratory flow at 25-75% of the FVC (FEF25-75). Before and after hypoxic exposure on visits 2 
255 and 3 subjects repeated FVC maneuvers following each of the diffusion capacity measurements 
256 (Miller and others 2005). Predicted values for all pulmonary function measures were based on 
257 predicted equations from NHANES III (Hankinson and others 1999). 
259 
258 Exhaled Breath Condensate (EBC) 
259 Exhaled breath condensate samples were collected using a Jaeger EcoScreen cooling unit 
260 (Cardinal Health, Yorba Linda, CA) as we have previously described (Wheatley and others 
261 2010a). During the 20 minute collections, subjects sat wearing a nose clip and breathed through a 
262 mouthpiece so all their exhaled breath could be directed to the Teflon condenser inside the 
263 EcoScreen cooling unit. Collections were made at baseline and the next morning following 
264 hypoxic exposure before subjects were removed from the tent. Samples were frozen at -80°C and 
265 then batch analyzed with quantification of chloride completed using ion chromatography and 
266 sodium measured with inductively-coupled plasma mass spectrometry.  
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269 
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283 
284 
285 
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287 
288 
Pulmonary Arterial Pressure 
Pulmonary arterial pressure was calculated from the tricuspid regurgitation (TR) velocity 
as described previously (Yock and Popp 1984) using the equation AP=A4V , where P is the 
pressure and V (m/s) is the tricuspid regurgitant velocity. The same sonographer performed the 
echocardiographic measures at baseline and after the fifteen hours of hypoxic exposure being 
performed before the subject was removed from the tent. There were three sonographers who 
performed these measurements on the subjects, all of them using the following methods for their 
assessment. Color Doppler was used to locate the tricuspid regurgitation jet. Data reported are 
from sixteen out of twenty subjects for whom a jet could be visualized and successfully 
measured. The maximal velocity was determined by careful application of the continuous wave 
sampler within and parallel to the regurgitation jet. 
Statistical Analysis 
The SPSS statistical software package (v.22; SPSS, Inc., Chicago, IL) was used for all 
statistical analyses. Two-factor repeated measure ANOVA was used to evaluate the main effects 
of normobaric hypoxia, drug (amiloride vs. placebo) and their interaction on the measures of lung 
fluid and systemic response to the conditions. Paired samples t-tests were performed between 
percent change from baseline to post exposure to hypoxia metrics (LLS, urine input/output) for 
the two treatments, with an alpha level of 0.05 used to determine statistical significance. All 
values presented are mean ±SD unless otherwise stated.  
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289 Results 
290 
290 Subject characteristics for the twenty subjects who participated in this study are provided 
291 in Table 1. 
293 
292 Changes in Lung Fluid in Response to Normobaric Hypoxia and Amiloride 
293 Normobaric hypoxia did not change DLCO, DLNO, or alveolar-capillary membrane 
294 conductance (DM) for both amiloride and placebo conditions (Figure 2). By contrast, hypoxic 
295 exposure caused an increase in pulmonary capillary blood volume (VC) (hypoxia effect p<0.01); 
296 the magnitude of increase in Vc was not different in amilioride vs. placebo (54±29% vs. 
297 54±52%, p= 0.52) (Figure 2). There was a reduction in CT derived tissue volume in response to 
298 hypoxic exposure (hypoxia effect p=<0.01) that was similar between amiloride and placebo 
299 conditions (-49.3±25.7 vs. -46.1±31.2 mL, p=0.69) (Figure 3). This decrease in tissue volume 
300 was not uniform across the lungs, with a minimal reduction (~2 ml) in the mid-right lobe, a 10 to 
301 13 ml reduction in the left lobes and upper right lobe, and a trend for a larger decrease, especially 
302 with amiloride, in the lower right lobe (~16ml) (Figure 4). There was a similar and significant 
303 decrease in EVLW from before to after hypoxic exposure (hypoxia effect p<0.01) with amiloride 
304 and placebo (-8.5±3.8% vs. -7.9±5.2%, p=0.53) (Figure 3). CT attenuation distributions showed 
305 the same trend for EVLW. Distribution average was shifted more negative, more leftward 
306 skewed, and more kurtotic after hypoxic exposure in both groups suggesting clearance of fluid 
307 from the lungs due to the shift towards less attenuation (hypoxia effect p<0.05, Table 3). There 
308 was no difference in these changes between amiloride and placebo conditions (p>0.05). 
309 Additionally, there was a decrease in plasma volume with hypoxic exposure (hypoxia effect 
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 p<0.01) for both conditions amiloride vs. placebo (-9.2±9.7 vs. -11.0+11.0 p= 0.52) suggesting 
that the decrease in EVLW was not just a shift of fluid from the interstitial to vascular space. 
Although there was a decrease in interstitial lung fluid with hypoxia and no effect of 
amiloride in the gross measures of changes in EVLW or on diffusion capacity or alveolar-
capillary membrane conductance, a measure of alveolar fluid, there were still signs of ENaC 
inhibition. First, utilizing EBC Na+ to assess changes in alveolar lung fluid suggested a trend for 
a decrease with placebo, but an increase with amiloride as was expected with amiloride inhibiting 
ENaC mediated-sodium absorption at the level of the alveolar epithelium. Second, in the fourteen 
subjects fluid input and output was recorded and although the pairwise comparison was not 
significant (p =0.44, Table 4), review of the individual responses under each condition shows the 
variability, and demonstrates that in eight subjects fluid loss was greater with amiloride 
compared to only four participants where fluid loss that was greater with the placebo than with 
amiloride, and two participants who showed no real difference between conditions (Figure 5). 
Systemic Responses to Normobaric Hypoxia Exposure 
The systemic responses to the normobaric hypoxia exposure are presented in Table 4. 
There was no change in cardiac output with hypoxic exposure (hypoxia effect p>0.05) and no 
difference between conditions amiloride vs. placebo (p=0.99), and the increase in systolic 
pulmonary arterial pressure was small (hypoxia effect p=0.02) and not different between 
amiloride vs. placebo visits (p=0.41). Hypoxic exposure caused a significant increase in HR with 
normobaric hypoxia (hypoxia effect p<0.01) that was not different between conditions (p=0.23). 
There was a trend for a reduction in norepinephrine concentration from pre- to post-hypoxia in 
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334 the amiloride condition (p=0.46), with no other change in catecholamine concentration was 
335 observed. Under both experimental conditions, there was no change in respiratory rate, FVC, 
336 FEV1/FVC, FEF25-75 and FEF75, suggesting hypoxic exposure had minimal to no effect on lung 
337 and airway function (hypoxia and condition effect p>0.05). Hypoxic exposure caused a 
338 significant and sustained reduction in SpO2 (hypoxia effect p<0.01) that was similar between 
339 amiloride and placebo conditions (86±3 vs. 85±3%, p=0.29). Over the course of the hypoxic 
340 exposure (~15 h), SpO2 decreased below 80% for only 18.3±16.1 min and 15.8±15.3 min in 
341 amiloride and placebo, respectively. No individual presented with signs of HAPE, subjects 
342 demonstrated mild altitude sickness with low modified Lake Louise Scores. 
343 Discussion 
344 
344 In this study we demonstrated that 1) there was a reduction in lung fluid, specifically 
345 interstitial lung fluid, with exposure to normobaric hypoxia and 2) the use of nebulized amiloride 
346 to inhibit ENaC did not affect lung fluid regulation. The results of this study replicate our 
347 ODERUDWRU\¶VSULRUILQGLQJVWKDWH[SRVXUHWRQRUPREDULFK\SR[LDDVZHOODVK\SREDULFK\SR[LD 
348 promotes lung fluid clearance rather than accumulation for the majority of individuals (Snyder 
349 and others 2006; Snyder and others 2008; Taylor 2013), but did not follow our original 
350 hypothesis that ENaC inhibition by amiloride would result in greater lung fluid accumulation. 
351 The novel findings in this study was the observation that lung fluid regulation was unaffected by 
352 ENaC inhibition via inhaled amiloride. The following discussion will highlight the potential 
353 mechanisms of lung fluid removal, the importance of ENaC and the ability of hypoxia to 
354 challenge alveolar fluid clearance. 
355 First, what is mediating removal of fluid with exposure to hypoxia?  
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CoQVLVWHQW ZLWK RXU ODERUDWRU\¶V SUHYLRXV ILQGLQJV ZH GHPRQVWUDWHG D UHGXFWLRQ LQ
interstitial lung fluid through CT derived measures of EVLW with exposure to hypoxia. 
However, in this current study alveolar fluid clearance rate appeared to be unchanged as there 
was no change in DLCO or DM with exposure to hypoxia. One possible explanation for this is 
that although in both studies subjects were kept in hypoxia until and between all measurements, 
in the current study the DLCO gas mixture used for post hypoxia measurements was the same as 
baseline where the oxygen concentration was 35%, where as in the previous study a special 
hypoxic DLCO gas mixture was used where the oxygen concentration was 18%. Since the 
change previously observed was not drastic (+10%), the potential of reoxygenation over the 10 
breaths of the non-hypoxic DLCO gas may have limited our ability to measure a change with 
hypoxia in the current study. The results of these studies seem to highlight that the observed fluid 
reduction is predominantly interstitial fluid removal. As such, lymphatic drainage is potentially of 
greater importance and the primary mediator of the observed reduction in lung fluid. Previous 
work in sheep and dogs has shown that lymph flow increases 10-40% with hypoxia (Levine and 
others 1988; Martin and others 1986) and the increases in ventilation experienced with hypoxia 
also facilitate pumping and production of lymph (Ikomi and others 1991; Mahe and others 1991; 
Pearse and others 2005; Zawieja 2009). Additionally, in our previous study we observed an 
increase in exhaled nitric oxide with normobaric hypoxia exposure (Snyder and others 2006; Van 
Iterson and others 2017). In the thoracic lymphatic duct of rat, initiation of spontaneous 
contraction of the phasically non-active segments results in nitric oxide mediated relaxation of 
these segments. This reduction in lymphatic vessel tone improves diastolic filling of the vessels 
and although contraction rate is reduced, lymphatic contractions are stronger making overall 
lymphatic pumping more efficient (Gashev 2008; Gasheva and others 2006). As such, we 
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380 hypothesize that the reduction in interstitial lung fluid observed in this study and in previous 
381 work in response to normobaric hypoxia is primarily driven by increases in lymphatic fluid 
382 clearance mediated by 1) increases in minute ventilation likely elevated due to increases in tidal 
383 volume, since we did not observe an increase in respiratory rate and 2) increases in NO 
384 mediating relaxation of the lymphatics such that they can more efficiently clear any excess 
385 interstitial fluid that is not reabsorbed. 
386 Is impairment of ENaC function really insufficient to cause pulmonary edema in response to 
387 hypoxic exposure? 
388 First, at least two types of Na+ channels have been identified to exist in the alveolar epithelium 
389 each with very different regulation, and quite often opposite response to the same stimuli (Eaton 
390 and others 2004; Trac and others 2017). ENaC is composed of three homologous subunits: a- 
391 ENaC, P-ENaC and y-ENaC. It is the ratio and combination of these subunits that can produce 
392 channels with varying conductances and regulatory properties. When a channel is composed of 
393 all three subunits then the channel has high Na+ selectivity and falls into the highly selective 
394 channel (HSC) type. In contrast, nonselective cation channels (NSC), or amiloride insensitive 
395 channels, are composed of at least one a-ENaC subunit and at least one acid-sensing ion channel 
396 1(ASIC1a) and the channel has low Na+ selectivity or no selectivity, making it likely to secrete 
397 K+ rather than absorb Na+(Trac and others 2017). Hypoxia can cause a shift from HSC to NSC 
as 
398 hypoxia reduce HSC or ENaC channelsm, but increase NSC expression (Jain and others 2001; 
399 Trac and others 2017), and reduces sodium transport across the airway epithelium (Tomlinson 
400 and others 1999b). In rats it was demonstrated that amiloride caused a greater drop in 
401 transepithelial Na+ flux, measured by nasal potential difference (NPD), than hypoxia alone. With 
402 hypoxia and amiloride there was no additional reduction in Na+ current, suggesting that the 
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reduction in Na+ with hypoxia was amiloride-sensitive ENaC mediated (Tomlinson and others 
1999a). Further, prior work has demonstrated that total or mean NPD is reduced in HAPE-prone 
subjects prior to altitude exposure, suggesting reduced resorption, with only Sartori et al showing 
a significant reduction in the amiloride-dependent Na+ transport (Mairbaurl and others 2003; 
Sartori and others 2004). Upon ascent to altitude results continued to conflicted at times, as 
Sartori et al observed a further decreased in total NPD, specifically only the amiloride- 
insensitive Na+ current by ~30%, with no change in the amiloride sensitive Na+ current, and this 
was only HAPE-prone subjects (Sartori and others 2004). In contrast, Mairbaurl et al found that 
total NPD became more positive due to increased chloride secretion, occurring in response to 
nasal dryness, and an observed increase in the amiloride insensitive Na+ current in both control. 
The amiloride-dependent Na+ reabsorption decreased in control subjects, while remained 
unchanged in HAPE-prone individuals (Mairbaurl and others 2003). Additionally, previous cell 
and tissue work has found that the 40-50% of the Na+ and airway fluid clearance occurs through 
amiloride-insensitive channels (O'Brodovich and others 2008; Sakuma and others 2006), with 
one study in human ATII cells demonstrating the amiloride-insensitive made up 70% of the fluid 
transport (Fang and others 2006). Data is conflicting as to which channel Na+ is moving through 
to mediate fluid clearance, but recent work by Trac et al. demonstrated that NSC reduction 
through knocking down either a-ENaC or ASIC1a reduces alveolar fluid clearance and causes 
wetter lungs. Further, unlike with ENaC (HSC) where its expression and numbers decrease with 
hypoxia, NSC increase expression in response to hypoxia and albeit likely not as effectively they 
are able to assist in preventing alveolar edema (Trac and others 2017). Focusing on the human in 
vivo and in vitro work as well as the results of this study suggest that although present, amiloride 
sensitive Na+ transport is not the sole means of alveolar fluid clearance, especially in response to 
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426 normobaric or hypobaric hypoxia. Measurement of nasal potential difference was not performed 
427 in this study limiting our ability to directly assess respiratory transepithelial baseline Na+ 
428 transport and the effects amiloride administration had on this in response to the normobaric 
429 hypoxia exposure. 
430 Second, one has to also question whether the amiloride dose sufficient for inhibition - 
431 how much reached the alveoli and how long was it acting locally on the airway epithelia before 
432 being absorbed and circulated systemically. Nebulized amiloride was originally developed for 
433 potential use in individuals with cystic fibrosis, where it was hoped it could inhibit the 
434 pathological hyperabsorption of Na+ that occurs through ENaC in these individuals. 
However, 
435 nebulized amiloride showed very poor efficacy in clinical trials and this was attributed to its 
low 
436 potency and short half-life duration on the airway epithelia (Graham and others 1993; Hirsh 
437 2002; Knowles and others 1990a; Kohler and others 1986; Pons and others 2000). Understanding 
438 these limitations of amiloride, but wanting to inhibit ENaC locally with a nebulized amiloride 
439 dose FDA approved, amiloride was administered three times (five and seven hours apart) during 
440 WKHVXEMHFW¶VK\SR[LDH[SRVXUH(YHQZLWKWKLVUHSHDWGRVLQJGUXJGHOLYHU\PD\KDYHEHHQ 
441 limited by the aerosol droplet size (larger portion of droplets being outside the respirable 
range 
442 of 1-5pm), and the lack of a standardized pattern of breathing, which could have reduced 
443 alveolar deposition such that the required concentration for effective blockade of 10pmol/L in 
444 the alveoli may not have been reached, and ENaC blockade was then only partial (Noone and 
445 others 1997; Schulz 1998). The timeline line of SpO2 and change from baseline (A SpO2) every 
446 two hours during the hypoxia exposure shows a trend from a drop in SpO2 following the 
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447 amiloride administrations, but this occurs with both placebo and amiloride (Figure 6). Although 
448 complete ENaC blockade was unlikely, the results suggest amiloride was having an inhibitory 
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effect locally as there was a trend for higher EBC Na+, a non-invasive assessment of airway 
surface liquid composition, with amiloride compared to placebo. This measurement has its 
limitations as although the composition of EBC is considered to be a dilute surrogate marker of 
ASL composition, one cannot be certain what region(s) of the lung the droplets are being formed. 
Future work should follow up with nasal potential difference measurements to provide an 
additional measure of changes in ion flux in the airway epithelium in response to hypoxia with 
and without amiloride. We also have signs that the nebulized amiloride was being absorbed 
across the epithelia and acting on the kidneys to cause diuresis as there is a trend for a higher net 
urine output with amiloride. This observed diuretic effect aligns with earlier pharmacokinetic 
work showing that after aerosol delivery, amiloride plasma concentration peaks by 30 minutes 
and 50% of amiloride has been excreted by four to six hours post administration (Noone and 
others 1997). 
Although this study did not show that ENaC was necessary for preventing lung fluid 
accumulation, it does not discount the role of ENaC in regulating alveolar lung fluid clearance. 
ENaC has been demonstrated to be necessary for fetal alveolar lung fluid clearance, where knock 
out of alpha ENaC caused a failure to thrive in mice (Mall and others 2004), but this study and 
the work of others suggests that the role of amiloride-sensitive ENaC is not primary or solely 
responsible for maintaining lung fluid homeostasis in response to normobaric or hypobaric 
K\SR[LD (1D&¶V UROH LQ OXQJ IOXLG EDODQFH LV DOYHRODU IOXLG FOHDUDQFH DQG LQ UHVSRQVH WR
normobaric hypoxia we do not observe that this role is challenged, such that it is not needed or 
necessary to maintain lung fluid balance. The current study and previous work have demonstrated 
that exposure to normobaric hypoxia promotes lung fluid clearance rather than accumulation for 
the majority of individuals (Snyder and others 2006; Snyder and others 2008)  
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472 meaning that even with amiloride inhibition of ENaC, complete or partial, alveolar fluid 
473 clearance is not really challenged as there is not a buildup of interstitial fluid that can potentially 
474 move into the alveoli. As such, we conclude that ENaC may not be necessary to maintain gross 
475 lung fluid homeostasis in response to normobaric hypoxia in healthy, non-HAPE susceptible 
476 individuals, but instead its role in more fine tuning and alveolar fluid balance and in this 
477 exposure there was no alveolar edema to prevent. 
478 Third, was the hypoxic stimulus sufficient to challenge alveolar fluid clearance? 
479 Exaggerated pulmonary hypertension plays an important role in the development of high- 
480 altitude pulmonary edema (HAPE) (Sartori and others 2000; Sartori and others 2004; Scherrer 
481 and others 1999). If the hypoxia stimulus is not sufficient, pulmonary arterial pressure would not 
482 be increased due to hypoxic pulmonary vasoconstriction and there would not be a large shift of 
483 fluid into the interstitial space (Maggiorini and others 2001). The estimated capacity of the 
484 lymphatics to absorb fluid is between 0.20-0.40mL/kg per hour for each pleural space (Shields 
485 2009). Although the conditions (hypoxic tent, CRU environment, level of hypoxia) were the 
486 same between this study and our previous study, the degree of hypoxemia experienced by the 
487 subjects in the current study was slightly less, with an average SpO2 around 85% overnight and 
488 less than 20 minutes at a SpO2 less than 80% in the current study compared to an average of 82% 
489 overnight in the previous study. In the current study, participants demonstrated an increase in 
490 HR of less than 15 bpm, a small increase in PAP, no change in respiratory rate and no rise in 
491 catecholamines whereas in our previous work we saw an average 14 bpm increase in HR, a 
492 doubling of PAP, and an increase in both EPI and NE with 17 hours of normobaric hypoxia 
493 exposure (Snyder and others 2006). Mazzeo et al. demonstrated that in response to an acute high 
494 altitude exposure, there is a rapid (within 4 hr) and significant increase in arterial EPI 
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concentrations (Mazzeo and others 1994). Hypoxia directly stimulates the adrenal medulla to release EPI 
into the circulation, with the increase in EPI concentration directly related to the severity of 
hypoxia exposure (i.e. the decline in arterial O2). In calves, Bloom et al. demonstrated that only 
in response to intense hypoxia (arterial PO2 17.1±2.8mmHg) did the adrenal medulla secrete 
physiologically effective amounts of catecholamines (Bloom and others 1977). With an average 
peripheral desaturation greater than 80%, it is unlikely that there was a severe decline in arterial 
O2 (80% SpO2 = PaO2 ~50mmHg), and as such not a strong enough stimulus for EPI release 
from the medulla. Alveolar fluid clearance, where ENaCs plays a role, would only be challenged 
when net fluid balance is disrupted such that there is more fluid moving from the pulmonary 
vessels to the interstitial space than can be removed by the lymphatic vessels; as then this excess 
fluid has the potential to shift into the alveolar space. With no change in catecholamines and no 
increase in pulmonary arterial pressure and a reduction in lung fluid in the current study, the 
hypoxia exposure likely did not challenge alveolar fluid clearance such that amiloride mediated 
impairment in alveolar transepithelial Na+ transport would compromise lung fluid clearance. 
Additionally, further work is needed to evaluate the role of ENaC in lung fluid, both alveolar and 
interstitial, to determine if these observations also hold true in HAPE- susceptible individuals. 
Conclusion 
Acute normobaric hypoxia caused a reduction in lung fluid volume that was unaffected by 
ENaC inhibition via inhaled amiloride, suggesting amiloride-sensitive ENaC were not necessary 
to maintain a balance between lung fluid accumulation and lung fluid clearance. We demonstrate 
a reduction in lung fluid, and as such it is likely that alveolar fluid clearance, where ENaC would 
be involved, was not significantly challenged. It is possible amiloride-sensitive  
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520 ENaC yam  not be necessary to maintain lung fluid balance in response to hypoxia, but it is more 
521 probable that normobaric hypoxia promotes lung fluid clearance rather than accumulation for the 
522 majority of individuals. 
523 
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532 
Tables 
Table 1 
Population Demographics 
 All Male Female 
n 20 11 9 
Age (years) 27±5 29+6 25+3 
Height (cm) 172±8 176+7 166+4* 
Weight (kg) 71+13 80+8 58+6* 
BMI (kg/m2) 24±3 26+3 21+3* 
BSA (m2) 1.8+0.2 2.0+0.1 1.6+0.1 
* VO2PEAK (% predicted) 106+19 102+20 111+17 
FVC (% predicted) 104+15 106+15 102+16 
FEV1 (% predicted) 102+15 104+17 99+14 
FEF27-75 (% predicted) 97+22 101+25 93+18 
Hemoglobin (g/dl) 14.0+1.2 15.0+0.8 13.1+0.8* 
 
533 
534 
FVC=forced vital capacity; FEVi=forced expiratory volume after one 
second of FVC; FEF25-75= forced expiratory flow at 25-75% of FVC. Data 
are presented as mean±SD. * p<0.05 vs. Males 
Embedded table for figure 3 
Table 2: Absolute Changes Placebo Amiloride 
 
Baseline Post Baseline Post 
Tissue Volume (mL) * 834+137 788+145* 837+137 788+144 
Extravascular lung water (mL) 797+137 736+143* 802+137 736+142* 
*p<0.05 hypoxia effect 
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FWHM = full width half-max. Data are presented as mean+SD.* p<0.05 vs. baseline
Table 3 Differences in EVLW using a histogram analysis of CT attenuation distributions 
Placebo Amiloride 
 
Baseline Post Baseline Post 
Average (HU) -889.0+23.4 -894.2+21.1* -886.3+26.5 -898.3+21.3* 
Skew 4.3+0.6 4.6+0.79* 4.3+0.60 4.6+0.69* 
Kurtosis 30.9+8.0 35.3+10.1* 31.2+8.9 35.0+10.0* 
FWHM (HU) 58.9+12.8 57.8+14.9 61.0+12.1 57.2+13.4 
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Table 4 Systemic Responses to Normobaric Hypoxia 
Systemic Response to Normobaric H ypoxia 
Placebo Amiloride 
 
Baseline Post Difference Baseline Post Difference 
Cardiac Output (L/min) 4.6+1.4 4.2+1.1 -0.3+1.0 4.2+0.9 3.8+1.3 -0.3+1.1 
Systolic Pulmonary Artery 
      
Pressure (mmHg) 15.9+9.9 17.6+11.5 3.6+5.3 10.6+7.2 16.3+11.5* 6.0+11.0 
HR (bpm) 67±9 78+14* 10+9 65+12 79+15* 14+12 
SpO2 (%) 98+1 92+4* -11+5 99+1 92+3* -14+4 
EPI (pg/mL) 32.5+25.7 32.7+24.1 0.20+33.0 36.4+50.0 31.0+24.4 -5.4+47.5 
NE (pg/mL) 242.2+82.5 207.0+101.4 -35.2+92.6 246.1+133.1 184.9+63.1* -61.3+114.5 
Respiratory Rate (breath/min) 15.9+1.6 16.7+1.8 0.8+1.8 15.7+1.8 16.8+1.6 1.1+2.5 
FVC (L) 4.9+0.3 4.7+0.3 -0.11+0.05 4.8+0.3 4.8+0.3 -0.08+0.05 
FEV1 (L) 3.9+0.2 3.9+0.2 -0.02+0.04 3.9+0.2 3.9+0.2 -0.03+0.05 
FEV1/FVC (%) 81.7+1.4 83.3+1.4 0.6+0.8 82.1+1.4 82.7+1.4 1.6+0.4 
FEF25-75 (L/sec) 3.9+0.2 4.1+0.2 0.2+0.1 3.9+0.2 4.0+0.2 0.02+0.10 
FEF75 (L/sec) 1.9+0.1 2.1+0.1 0.1+0.1 2.0+0.1 2.0+0.1 0.1+0.1 
PEF (L/sec) 9.0+0.6 8.7+0.6 -0.2+0.2 8.6+0.5 8.6+0.6 0.03+0.2 
EBC Na+ (mmol/L) 0.71+0.29 0.58+0.25 -9.7+43.2% 0.61+0.21 0.72+0.51 20.1+92.5% 
Fluid Input-Output (mL) -136.3+732.4 
 
-272.8+319.6 
 
Modified Lake Louise Score 1.0+1.2  1.1+1.2  
Percent of Time SpO2<80% 15.8+15.3 
 
18.3+16.1 
 
SpO2= peripheral oxygen saturation; HR= heart rate; EPI= epinephrine; NE= norepinephrine; FVC=forced vital capacity; 
FEV1=forced expiratory volume after one second of FVC; FEF25-75= forced expiratory flow at 25-75% of FVC; FEF75= forced 
expiratory flow at 75 % of FVC; PEF= peak expiratory flow; EBC Na+= exhaled breathe condensate Na+; Modified Lake 
Louise Score is out of 30 and averaged over their tent exposure; Percent of time SpO2<80%= percent of time in tent that nonin 
wrist stats dropped below 80%. Data are presented as mean±SD.* p<0.05 vs. baseline 
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Figure Legends 
Figure 1 Hypoxia Visit Schematic 
Figure 2 Diffusion Capacity of the Lungs for Carbon Monoxide (DLCO) and Nitric Oxide 
(DLNO) in Response to Normobaric Hypoxia 
Pre-hypoxia (white bars) to Post-hypoxia (black bars) for placebo and amiloride. Panel A: 
Diffusion capacity of the lungs for carbon monoxide (DLCO); Panel B: Diffusion capacity of the 
lungs for nitric oxide (DLNO); Panel C: Alveolar-capillary membrane conductance (DM); Panel 
D: Pulmonary-capillary blood volume (VC). Percent change listed for each above, placebo vs. 
amiloride respectively; * p<0.05 vs. baseline 
Figure 3 Changes in CT assessed Lung Tissue Volume (TV) and Calculated Extravascular 
Lung Water (EVLW) After Normobaric Hypoxia 
Difference from post hypoxia to pre hypoxia for placebo (white bars) and amiloride (black bars) 
for tissue volume (ATV) and extravascular lung water (EVLW = TV - VC). Percent change from 
baseline is listed for EVLW. And absolute change is found in table 2. 
Figure 4 CT Tissue Volume Changes Stratified by Lung Lobe after Normobaric Hypoxia 
Difference from post hypoxia to pre hypoxia for placebo (white bars) and amiloride (black bars) 
for tissue volume for lung lobes: LL= lower left; UL= upper left; UR= upper right; MR= middle 
right; LR= lower right. 
Figure 5 Individual Fluid Input-Output in Response to Normobaric Hypoxia 
Each line represents a subject, with the fluid input-output plotted for the amiloride visit and the 
Placebo visit and line connecting the two to show how the responses differed between conditions. 
Negative fluid loss greater in placebo vs. amiloride condition (dashed lines); negative fluid loss 
with amiloride and a positive with placebo or less fluid gain with amiloride (black lines). No 
difference in I/O between conditions (grey lines). 
Figure 6 SpO2 and change from Baseline (ASpO2) During the Normobaric Hypoxia 
Exposure 
The average SpO2 noted by the CRU nurse every two hours in subjects during their amiloride 
visit (black squares) and placebo visit (open black circles). Black arrows represent the time when 
amiloride/placebo was nebulized. The change in SpO2 from baseline every two hours is presented 
for amiloride (grey squares) and placebo (open grey circles). Standard deviation is not presented 
on figure to keep figure clear. Amiloride SD: mean ±4.4; range (1.2-5.6). Placebo SD: mean 
±4.4; range (3.2-5.9). Amiloride delta SD: mean ±5.1; range (3.9-6.0). Placebo delta SD: mean 
±6.3; range (4.9-8.1).  
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Figure 1 Hypoxia Visit Schematic 211x74mm (96 x 96 DPI) 
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Supplement: 
High Altitude Symptoms Worksheet: Lake Louise Acute Mountain Sickness Questionnaire 
COLUMN 1 COLUMN 2 COLUMN 3 
1. Headache 
No headache 
Mild headache 
Moderate headache 
0 
1 
2 
Severe, incapacitating 3 
2. GI (stomach) 
 
No problems 0 
Poor appetite, nausea 1 
Moderate nausea, vomiting 2 
Severe N & V, incapacitating 3 
3. Fatigue/weak 
Not tired or weak 0 
Mild fatigue/weakness 1 
Moderate fatigue/ weakness 2 
Severe F/W, incapacitating 3 
4. Dizzy/lightheaded 
Not dizzy 0 
Mild dizziness 1 
Moderate dizziness 2 
Severe, incapacitating 3 
 
5. Difficulty sleeping 
Slept well as usual 
Did not sleep as well as usual 
Woke many times, poor night's sleep 
Could not sleep at all 
0 
1 
2 
3 
6. Short of breath at rest 
 
Breathing as usual 0 
Mildly short of breath 1 
Moderately short of breath 2 
Severely short of breath 1 3 
7.Edema/swelling (hands, arms, face, feet) 
No swelling 0 
Swelling in 1 spot 1 
Swelling in 2 spots 2 
Swelling in multiple spots 3 
8. Change in mental status 
 
No problems 0 
A little slow of thinking 1 
Definitely confused at times 2 
Very confused and lethargic 3 
 
9.Cough 
 
No change from usual 0 
More than usual 1 
Significantly more than usual 2 
Unable to stop coughing 
J10. General health  
I feel OK 0 
A little ill but can do everything 1 
Somewhat ill, limited 2 
Feel bad, can't function normally 3 
 
Column 1 Total 
n
 
Column 2 Total 
n
 
Column 3 Total Ŀ Column 1  
Column 2 
 
Column 3 
 
Overall total score 
 
 
Study Stopping Criteria 
If number in any grey box is circled, STOP STUDY 
If total score is >25, STOP STUDY 
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